Gynecologic Oncology

• 

  Publication Venue For

  • Guidelines for goals of care discussions in patients with gynecologic cancer..  174:247-252. 2023
  • Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score..  174:114-120. 2023
  • The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes..  166:417-424. 2022
  • Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)..  163:237-245. 2021
  • Abstracts for the 2021 Society of Gynecologic Oncology 52nd Annual Meeting on Women's Cancer Foreword.  162:S1-S1. 2021
  • Patterns of use and outcomes of sentinel lymph node mapping for patients with high-grade endometrial cancer..  159:732-736. 2020
  • Perioperative outcomes and disparities in utilization of sentinel lymph node biopsy in minimally invasive staging of endometrial cancer..  159:758-766. 2020
  • COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies..  158:34-36. 2020
  • An integrated molecular profile of endometrioid ovarian cancer..  157:55-61. 2020
  • Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?.  154:177-182. 2019
  • Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes..  150:14-18. 2018
  • Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost-effectiveness analysis of the AURELIA trial.  141:36-36. 2016
  • Abstract 10: Does routine post-treatment PET/CT add value to the care of women with locally advanced cervical cancer?.  137:594-595. 2015
  • A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study..  133:537-541. 2014
  • The Omentum and omentectomy in epithelial ovarian cancer: A reappraisal Part I - Omental function and history of omentectomy.  131:780-783. 2013
  • The omentum and omentectomy in epithelial ovarian cancer: A reappraisal.  131:784-790. 2013
  • A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.  131:276-276. 2013
  • Genetic profiling to predict recurrence of early cervical cancer 2013
  • Response to "response to Rossi et al. (Gynecol Oncol. 2012; 124(1):78-82)".  125:765. 2012
  • Clinical translation of the cancer genome atlas signature for ovarian cancer survival.  125:S42-S42. 2012
  • DNA Methylation Profiles Distinguish Serous, Mucinous and Clear Cell but not Endometrioid Epithelial Ovarian Cancers.  125:S99-S99. 2012
  • Frequency of the cancer genome atlas expression subtypes differs between early and advanced stage high grade serous ovarian cancers.  125:S133-S133. 2012
  • Loss of p16 in advanced stage epithelial ovarian cancer is associated with chemoresistant disease, suboptimal debulking and poor progression-free survival: A Gynecologic Oncology Group study..  125:S37-S37. 2012
  • Erratum: Robotically assisted fluorescence-guided lymph node mapping with ICG for gynecologic malignancies: A feasibility study (Gynecologic Oncology (2012) 124, (78-82) DOI: 10.1016/j.ygyno.2011.09.025).  126:169. 2012
  • Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing.  121:S2-S3. 2011
  • BAD apoptosis pathway expression and survival from cancer.  120:S24-S24. 2011
  • Common single-nucleotide polymorphisms in the BNC2, HOXD1 and MERIT40 regions contribute significantly to racial differences in ovarian cancer incidence.  120:S7-S7. 2011
  • Concordant gene expression profiles in matched primary and recurrent serous ovarian cancers predict platinum response.  120:S46-S46. 2011
  • Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer.  120:S11-S11. 2011
  • DNA methylation markers associated with serous ovarian cancer subtypes.  120:S48-S48. 2011
  • Genes functionally regulated by methylation in ovarian cancer are involved in cell proliferation, development and morphogenesis.  120:S69-S69. 2011
  • Genomewide methylation analyses reveal a prominent role of HINF1 network genes, via hypomethylation, in ovarian clear cell carcinoma.  120:S8-S8. 2011
  • Loss of ARID1A is a frequent event in clear cell and endometrioid ovarian cancers.  120:S21-S21. 2011
  • A multicenter, randomized, phase II study evaluating the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.  116:S3-S3. 2010
  • Adverse events associated with laparoscopy versus laparotomy in the treatment of stage I endometrial cancer.  116:S147-S147. 2010
  • Gene expression profiling of invasive serous ovarian cancers from formalin-fixed, paraffin-embedded tissues using DASL.  116:S136-S137. 2010
  • Genomic SRC signature and SRC protein expression in ovarian cancers may predict response to the SRC inhibitor dasatinib.  116:S151-S152. 2010
  • Genomic analysis defines biological pathway differences between early- and advanced-stage ovarian cancers.  116:S22-S22. 2010
  • Indolent and aggressive phenotypes of epithelial ovarian cancer: Implications for screening.  116:S107-S107. 2010
  • Projecting the need for gynecologic oncologists for the next 40 years: Not enough, too many or just right?.  116:S52-S53. 2010
  • In response to "The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma".  115:317. 2009
  • 7-hydroxystaurosporine (UCN-01) is effective in targeting ovarian cancer spheroids.  112:S161-S162. 2009
  • Cost analysis of ovarian cancer chemotherapy based on the use of a chemoresponse assay.  112:S22-S22. 2009
  • Gene signature specific for ovarian clear cell carcinoma is induced by the contents of endometriotic cysts.  112:S132-S132. 2009
  • Genomic predictors of ovarian cancer response to salvage therapy.  112:S133-S133. 2009
  • High poly (ADP-ribose) polymerase (PARP) expression is associated with poor survival in advanced-stage serous ovarian cancer.  112:S107-S107. 2009
  • Imprinted Neuronatin: A potential epigenetie biomarker of ovarian cancer.  112:S135-S135. 2009
  • Intragenic methylation at a novel CTCF binding site is associated with elevated IGF2 expression in serous epithelial ovarian cancer.  112:S138-S138. 2009
  • Loss of GPR54 correlates with stem cell activity in high-grade endometrial cancer.  112:S78-S78. 2009
  • MiRNA patterns in ovarian cancer cell lines: Correlation with serum studies.  112:S115-S116. 2009
  • Minimally invasive staging for endometrial cancer is associated with lower pain, nausea and narcotic use.  112:S80-S80. 2009
  • Ovarian cancer tumor-infiltrating regulatory T cells are associated with a metastatic phenotype.  112:S11-S11. 2009
  • Validation of the MAL gene as a predictor of survival in advanced-stage high-grade serous ovarian cancer.  112:S123-S124. 2009
  • Corrigendum to "The current and future role of screening in the era of HPV vaccination" [Gynecol. Oncol. 109 (2008) S31-S39] (DOI:10.1016/j.ygyno.2008.02.001).  110:270. 2008
  • Can screening for ovarian cancer achieve mortality reduction and be cost effective?.  108:S114-S115. 2008
  • Cost effectiveness of annual screening strategies for endometrial cancer.  108:S7-S7. 2008
  • Gene expression analysis of stage I serous and endornetrioid endometrial cancers.  108:S76-S76. 2008
  • Methylation in ovarian cancer is related to poor prognosis and suppression of the transforming growth factor signaling pathway.  108:S104-S104. 2008
  • Microarray analysis defines patterns of gene expression associated with mutation of TP53 in ovarian cancer.  108:S84-S84. 2008
  • Microarray analysis identifies NSC668814 as a potentially active chemotherapeutic agent for platinum-resistant ovarian cancers with TP53 mutations.  108:S72-S72. 2008
  • Microarray analysis of microdissected stage I endometrial cancers reveals gene expression patterns associated with inflammation.  108:S80-S81. 2008
  • Ovarian Cancer Association Consortium analysis of seven candidate ovarian cancer susceptibility polymorphisms.  108:S29-S30. 2008
  • Regulation of angiogenic gene expression in p53 wild type and mutant ovarian cancer cells by hypoxia and radiation.  108:S84-S84. 2008
  • Targeting dormant ovarian cancer cells.  108:S13-S14. 2008
  • Corrigendum to "The current and future role of screening in the era of HPV vaccination" [Gynecol. Oncol. 109 (2008) S31-S39] (DOI:10.1016/j.ygyno.2008.02.001) 2008
  • The prognostic significance of p53 and cyclin E overexpression in ovarian cancer: A population-based study.  108:S125-S125. 2008
  • Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas..  107:52-57. 2007
  • Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer..  106:388-393. 2007
  • Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study..  106:221-232. 2007
  • Outcomes in surgical stage I uterine papillary serous carcinoma..  105:677-682. 2007
  • Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma..  105:563-570. 2007
  • Regulation of the metastasis suppressor gene MKK4 in ovarian cancer..  105:312-320. 2007
  • High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients..  104:691-694. 2007
  • Preclinical evaluation of biomarkers for ovarian cancer detection and monitoring for disease recurrence.  104:S12-S12. 2007
  • The role of multimodality adjuvant chemotherapy and radiation in women with advanced-stage endometrial cancer.  104:S6-S6. 2007
  • The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer..  104:401-405. 2007
  • Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk..  103:535-540. 2006
  • Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology..  102:92-97. 2006
  • Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study..  101:390-397. 2006
  • Optical imaging of cervical pre-cancers with structured illumination: an integrated approach..  99:S112-S115. 2005
  • Resection of lymph node metastases influences survival in stage IIIC endometrial cancer..  99:689-695. 2005
  • BRAF polymorphisms and the risk of ovarian cancer of low malignant potential..  97:807-812. 2005
  • Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity..  97:596-601. 2005
  • Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk..  97:543-549. 2005
  • FDG-PET for management of cervical and ovarian cancer..  97:183-191. 2005
  • High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer..  96:355-361. 2005
  • Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer - Reply.  96:265-266. 2005
  • Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer..  96:265. 2005
  • Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer..  94:121-124. 2004
  • The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer..  94:74-79. 2004
  • The role of optimal debulking in advanced stage serous carcinoma of the uterus..  94:170-174. 2004
  • Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery..  93:366-373. 2004
  • Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer..  93:429-434. 2004
  • Mucinous adenocarcinoma arising in rectovaginal fistulas associated with Crohn's disease..  93:266-268. 2004
  • Placental site trophoblastic tumor arising from antecedent molar pregnancy..  92:708-712. 2004
  • High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease..  91:258-260. 2003
  • Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls..  90:75-82. 2003
  • The role of PET scanning in the detection of recurrent cervical cancer..  90:186-190. 2003
  • The role of microsatellite instability in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix..  89:434-439. 2003
  • Specific keynote: genome copy number abnormalities in ovarian cancer..  88:S16-S21. 2003
  • Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer..  88:51-57. 2003
  • Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer..  84:321-326. 2002
  • Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations..  83:491-500. 2001
  • Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor..  83:466-471. 2001
  • DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization..  82:261-268. 2001
  • Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients..  82:273-278. 2001
  • Allele loss on chromosome 1p36 in epithelial ovarian cancers..  82:94-98. 2001
  • Cervical dysplasia in women infected with the human immunodeficiency virus (HIV): a correlation with HIV viral load and CD4+ count..  80:350-354. 2001
  • Vacuum-assisted closure for cutaneous gastrointestinal fistula management..  80:413-416. 2001
  • K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary..  80:201-206. 2001
  • Bilateral pelvic lymph node metastases in a case of FIGO stage IA(1) adenocarcinoma of the cervix..  77:467-470. 2000
  • p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma..  77:439-445. 2000
  • The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma..  77:55-65. 2000
  • Elevated serum CA-125 levels: hepatitis or ascites?.  76:141-142. 2000
  • Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma..  74:385-394. 1999
  • Cost-effectiveness of treatment of early stage endometrial cancer..  74:208-216. 1999
  • Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors..  74:98-102. 1999
  • Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses..  73:56-61. 1999
  • Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers..  70:13-16. 1998
  • Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines..  70:49-55. 1998
  • Cardiac metastasis from carcinoma of the cervix: report of two cases..  69:264-268. 1998
  • Molecular characterization of adenocarcinoma of the cervix..  64:242-251. 1997
  • Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2..  62:89-99. 1996
  • Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study..  59:194-199. 1995
  • Gestational trophoblastic disease metastatic to the central nervous system..  59:226-230. 1995
  • p53-based gene therapy of ovarian cancer: magic bullet?.  59:169-170. 1995
  • Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses..  59:111-116. 1995
  • Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma..  59:20-24. 1995
  • Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels..  58:79-85. 1995
  • Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease..  56:421-424. 1995
  • Long and short gracilis myocutaneous flaps for vulvovaginal reconstruction after radical pelvic surgery: comparison of flap-specific complications..  56:271-275. 1995
  • Racial differences in tumor grade among women with endometrial cancer..  56:154-163. 1995
  • Interphase fluorescence in situ hybridization for trisomy 12 on archival ovarian sex cord-stromal tumors..  55:349-354. 1994
  • 5-day methotrexate for women with metastatic gestational trophoblastic disease..  54:76-79. 1994
  • Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha..  53:59-63. 1994
  • Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors..  52:232-236. 1994
  • Second-look laparotomy in ovarian cancer.  55:S122-S127. 1994
  • Prevention of superficial wound separation with subcutaneous retention sutures..  51:330-334. 1993
  • Lymph node sampling in patients with epithelial ovarian carcinoma..  47:143-145. 1992
  • Ha-ras polymorphisms in epithelial ovarian cancer..  45:299-302. 1992
  • Ploidy analysis of epithelial ovarian cancers using image cytometry..  44:61-65. 1992
  • Concentrated albumin infusion as an aid to postoperative recovery after pelvic exenteration..  43:265-269. 1991
  • Expression of interleukin-1 and interleukin-1 receptor antagonists in endometrial cancer..  42:161-164. 1991
  • The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma..  41:239-244. 1991
  • Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause..  40:42-45. 1991
  • High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer..  38:386-391. 1990
  • Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer..  37:390-395. 1990
  • CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer..  36:161-165. 1990
  • Treatment of endometrial stromal tumors..  36:60-65. 1990
  • Pelvic exenteration: factors associated with major surgical morbidity..  35:93-98. 1989
  • Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate..  35:75-77. 1989
  • Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide..  29:32-36. 1988
  • Total parenteral nutrition in poor prognosis gestational trophoblastic disease..  28:305-311. 1987
  • Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival..  26:11-18. 1987
  • Peritoneal cytology and invasive carcinoma of the cervix..  24:331-336. 1986
  • Defective release of vascular plasminogen activator in patients with gynecologic malignancies..  23:141-148. 1986
  • Cervical adenoid cystic carcinoma associated with ascites..  22:201-211. 1985
  • Pathology of colposcopic findings in 2635 diethylstilbestrol-exposed young women..  21:277-286. 1985
  • Nuclear DNA content of clear cell adenocarcinoma of the vagina and cervix and its relationship to prognosis..  15:230-238. 1983
  • Role of hormones including diethylstibestrol (DES) in the pathogenesis of cervical and vaginal intraepithelial neoplasia..  12:S98-110. 1981
  • Dysplasia and cytologic findings in 4,589 young women enrolled in diethylstilbestrol-adenosis (DESAD) project.  10:361. 1980
  • A pilot study of a collaborative screening program for HPV-related dysplasia and malignancy in gynecologic oncology patients 2022
  • A quality improvement initiative to increase genetic testing referrals after identification of hereditable high-risk mutations on next generation sequencing (NGS) 2022
  • An initiative to improve adherence to guidelines for thromboprophylaxis among high-risk gynecologic oncology patients receiving outpatient chemotherapy 2022
  • Genomic alterations, molecularly targeted therapy and race: Real world data from the Endometrial Cancer Molecularly Targeted Therapy Consortium 2022
  • Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer 2022
  • Ipatasertib, an oral AKT inhibitor, in combination with Bevacizumab exhibits anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium 2022
  • Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in serous endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium 2022
  • Ipatasertib, an oral AKT inhibitor, in combination with paclitaxel exhibits anti-proliferative and anti-tumorigenic effects in preclinical studies for endometrioid endometrial cancer: Endometrial cancer molecularly targeted therapy consortium 2022
  • Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets 2022
  • PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FR alpha) expression 2022
  • Pilot Cervical Cancer Navigation Program Outcomes from a Tertiary Tanzanian Academic Institute 2022
  • Prospective, randomized trial of streamlined genetic education and testing for patients with high grade epithelial ovarian, fallopian and peritoneal cancer 2022
  • A multi-institutional study of minimally invasive surgery compared to laparotomy for interval debulking after neoadjuvant chemotherapy in women with advanced ovarian cancer 2021
  • AdoRN Trial: Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly-diagnosed advanced-stage epithelial ovarian cancer 2021
  • Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study 2021
  • Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial 2021
  • Creation of an individualized algorithm for venous thromboembolism prophylaxis on a gynecologic oncology service 2021
  • Cytoreduction status and platinum sensitivity in women with recurrent ovarian cancer 2021
  • Development and validation of the Gynecologic Oncology Predictor Of Postoperative opioid use (GO-POP) model 2021
  • Dual germline and somatic testing in women with high-grade epithelial ovarian, tubal, and peritoneal cancer: a prospective systemic quality improvement initiative 2021
  • Gynecologic oncology clinical trials: study the studies to terminate the terminations 2021
  • HOPE & Healing: a randomized pilot study of structured palliative care referrals in recurrent ovarian cancer 2021
  • Ipatasertib, an oral AKT inhibitor, exhibits anti-proliferative and anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium 2021
  • Khorana score stratification and incidence of venous thromboembolism among women with ovarian cancer receiving neoadjuvant chemotherapy 2021
  • Racial differences in patient-reported distress among women with endometrial cancer 2021
  • The ABCs of ACPs: perspectives from gynecologic oncology clinicians on an advance care planning initiative 2021
  • A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma 2020
  • A systematic outpatient quality improvement intervention results in earlier goals of care conversations between high-risk gynecologic cancer patients and their providers 2020
  • Assessing the impact of cardiometabolic risk on ovarian cancer survival among African-American women in the African-American cancer epidemiology study (AACES) 2020
  • Development of a prediction model for postoperative opioid use following gynecologic surgery 2020
  • Gynecologic malignancy-associated bowel obstruction: Outcomes and prognostic implications 2020
  • Implementation of a quality improvement (QI) project of universal screening for Lynch syndrome in women with uterine cancer 2020
  • Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option? 2020
  • Pembrolizumab window study: Illuminating the immunologic landscape in gynecologic cancers 2020
  • Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis 2020
  • Results and clinical utilization of next-generation tumor sequencing in gynecologic oncology patients 2020
  • The gynecologic oncology patient experience with oral anti-cancer therapy: A quantitative and qualitative analysis of medication adherence 2020
  • The power of P: Preoperative patient pain perceptions predict inpatient pain medication requirements following gynecologic oncology surgery 2020
  • Turning ΡroΜisΕ into practice: Predicting response in medically managed endometrial cancers via molecular classification 2020
  • Addressing pain along the continuum of cervical cancer care among women ultimately presenting at mulago national referral hospital and the Uganda cancer institute 2019
  • Association between isolated tumor cells and recurrence in stage I endometrial cancer 2019
  • Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer 2019
  • CaMKK2-can: A dance between CaMKK2 and Rb in high-grade serous ovarian cancer patients with therapeutic potential 2019
  • Cardiovascular comorbidities and risk of ovarian carcinoma among African American women in the African American cancer epidemiology study (AACES) 2019
  • Early-stage endometrial cancer with lymphovascular space invasion: Chemotherapy improves progression free survival and reduces distant metastases 2019
  • Gonadotropin receptors as targetable biomarkers in advanced, high-grade serous ovarian cancer 2019
  • Maintenance therapy utilization in platinum-sensitive recurrent epithelial ovarian cancer: A 'real-world' analysis 2019
  • Molecular driven endometrial cancer therapy (MODEL): A prospective paradigm using molecular tumor profiling to direct therapy in women with advanced/recurrent endometrial cancer 2019
  • Novel management of morbidly adherent placenta: Preliminary outcomes assessment of 13-year experience with prospective multidisciplinary algorithm 2019
  • Rate of venous thromboembolism during neoadjuvant chemotherapy for advanced ovarian cancer 2019
  • Targeting family genomic alterations in gynecological malignancies 2019
  • To admit or not admit: An evaluation of avoidable and potentially avoidable admissions on a gynecologic oncology service 2019
  • Utilization of the LACE score to predict 30-day hospital readmission or death in gynecologic oncology patients 2019
  • Are FDA-approved PARPi cost-effective as maintenance treatment of platinum-sensitive recurrent ovarian cancer? 2018
  • Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers 2018
  • Obesity is associated with altered angiogenic gene expression in endometrioid endometrial cancer 2018
  • Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P 2018
  • Surgical candidacy among women presenting at Mulago National Referral Hospital and the Uganda Cancer Institute with new diagnoses of cervical cancer 2018
  • Targeting the TIE2 pathway with a novel small molecule vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibitor in high-grade serous ovarian cancer 2018
  • HPV positivity among women in Central Uganda participating in a Community Health Campaign offering self-collected HPV-based cervical cancer screening 2017
  • Imaging Biomarkers of Adiposity and Sarcopenia as Potential Predictors for Overall Survival Among Patients with Endometrial Cancer Treated with Bevacizumab 2017
  • Predicting Non-Home Discharge in Epithelial Ovarian Cancer Patients: External Validation of a Predictive Model 2017
  • Differential expression of immune-related genes in high-grade ovarian serous carcinoma (HGSC): A platform for drug and biomarker discovery 2017
  • Mortality reduction and cost-effectiveness of performing hysterectomy at the time of RRSO for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers 2017
  • Patient, caregiver and physician perceptions of palliative care in ovarian cancer: Insights from the HOPE prospective pilot study 2017
  • Placenta-specific protein 1 (PLAC1) expression in serous ovarian cancer is significantly determined by p53 mutation status 2017
  • Prospective patient-elicited value assessments of options in the primary treatment of ovarian cancer 2017
  • Use of a novel sentinel lymph node mapping algorithm reduces pelvic lymphadenectomy rates in patients with low-grade endometrial cancer 2017
  • A personalized paradigm in the treatment of platinum-resistant ovarian cancer: A cost utility analysis of genomic-based versus cytotoxic therapy 2015
  • Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? 2015
  • Cost comparison among different genetic testing strategies in women with epithelial ovarian cancer 2015
  • Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy? 2015
  • Evaluation of ERRα expression and association with survival in advanced ovarian cancer 2015
  • Findings at laparoscopy, not debulking status, are associated with survival in advanced stage ovarian cancer after neoadjuvant chemotherapy 2015
  • Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention 2015
  • KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA) 2015
  • Laparoscopy compared to laparotomy in the management of granulosa cell tumors of the ovary 2015
  • New cases of small cell carcinoma of the ovary, hypercalemic type caused by germline SMARCA4 mutations: An under-diagnosed entity? 2015
  • Relationship between body mass index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project 2015
  • Sentinel lymph node mapping in women with high risk histology endometrial cancer 2015
  • Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in leiomyosarcoma cell lines 2012
  • Utilization of genomic signatures to identify Fludarabine and Temsirolimus as candidate drugs with high efficacy to chemo-refractory endometrial cancers 2012
  • Metastin-10 suppresses invasion of endometrial cancer cells 2010
  • Progressive epigenetic deregulation of insulin-like growth factor 2 in cervical cancer precursors in HIV plus and HIV- patients 2010
  • Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling 2010
  • A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer 2009
  • Early-stage uterine papillary serous carcinoma (UPSC): percentage UPSC, lymphvascular invasion and tumor size are not independent predictors of recurrence 2009
  • Improved survival with consolidation chemotherapy after adjuvant paclitaxel and carboplatin in advanced epithelial ovarian cancer 2009
  • Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer 2009
  • The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma 2009
  • MAL, a gene associated with survival in epithelial ovarian cancer, is epigenetically regulated 2008
  • Prognostic relevance of microvessel density in previously untreated, advanced-stage epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study 2008
  • Surgical cytoreduction and dose intensity of adjuvant paclitaxel and carboplatin chemotherapy in advanced epithelial ovarian cancer 2008
  • Stem cell marker CD133 (PROMININ-1) is epigenetically regulated in ovarian cancer 2008
  • Most early-stage serous ovarian cancers have gene expression profiles predictive of long-term survival 2007
  • Phase II study of cetuximab in combination with carboplatin in patients with relapsed platinum-sensitive ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study 2007
  • Discussion: Ovarian Cancer Prevention 2003